Corbus Pharmaceuticals Q1 2026 Earnings SmallerThanExpected Loss Amid Pipeline Progress UCTT Q1 2026 Earnings EPS Beats Estimates by 16 as Company Delivers Solid Performance RXRX Q1 2026 Earnings EPS Beat Despite No Revenue Stock Slips 32 TM Q1 2026 Earnings EPS Beat Driven by Cost Controls and Robust Global Sales EICC Q4 2025 Earnings Marginal EPS Miss Amid Stable Preferred Stock Performance GLPI Q1 2026 Earnings Modest EPS Miss Highlights Operational Stability Stock Edges Higher